In the most recently reported quarter, several renowned institutional investors made notable increases to their Danaher (DHR) holdings, reflecting growing confidence in the life sciences and diagnostics conglomerate. As the company continues to evolve its portfolio through innovation and strategic divestitures, Danaher is attracting fresh institutional capital as a long-term compounder in the healthcare sector.
